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Abstract:  
Objective: 
More than 80% of autoimmune disease is female dominant, but the mechanism for this female 
bias is poorly understood. We suspected an X chromosome dose effect and hypothesized that 
trisomy X (47,XXX , 1 in ~1,000 live female births) would be increased in female predominant 
diseases (e.g. systemic lupus erythematosus [SLE], primary Sjögren’s syndrome [SS], primary 
biliary cirrhosis [PBC] and rheumatoid arthritis [RA]) compared to diseases without female 
predominance (sarcoidosis) and controls. 
Methods: 
We identified 47,XXX subjects using aggregate data from single nucleotide polymorphism 
(SNP) arrays and confirmed, when possible, by fluorescent in situ hybridization (FISH) or 
quantitative polymerase chain reaction (q-PCR). 
Results: 
We found 47,XXX in seven of 2,826 SLE and three of 1,033 SS female patients, but only in two 
of the 7,074 female controls (p=0.003, OR=8.78, 95% CI: 1.67-86.79 and p=0.02, OR=10.29, 
95% CI: 1.18-123.47; respectively). One 47,XXX subject was present for ~404 SLE women and 
~344 SS women. 47,XXX was present in excess among SLE and SS subjects. 
Conclusion: 
The estimated prevalence of SLE and SS in women with 47,XXX was respectively ~2.5 and ~2.9 
times higher than in 46,XX women and ~25 and ~41 times higher than in 46,XY men. No 
statistically significant increase of 47,XXX was observed in other female-biased diseases (PBC 
or RA), supporting the idea of multiple pathways to sex bias in autoimmunity. 
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Introduction 
Autoimmune disease affects 5-10% of the global population. Female preponderance is 
highlighted by the fact that almost 80% of autoimmune patients are female(1). Systemic lupus 
erythematosus (SLE), primary Sjögren's syndrome (SS), primary biliary cirrhosis (PBC), 
rheumatoid arthritis (RA) all have a female sex bias, though the ratios vary from fourteen women 
to one man in SS to only two to six women to one man in RA(2-5).  
 
Several hypotheses have been proposed to explain the female preponderance in autoimmunity, 
such as sex hormones(6) and X monosomy(7, 8), but origins remain unknown. We have 
previously shown that Klinelfelter’s syndrome (47,XXY) is found in excess among men with 
SLE, and the calculated prevalence of SLE among Klinefelter’ syndrome is similar to the 
prevalence in women (46,XX)(9). Data for SLE in four core genotype mice show that the disease 
is associated with the number of X chromosomes, and not phenotypic sex (10, 11). In aggregate 
these data are consistent with the gene dose of chromosome X being a major determining factor 
for the female predominance of SLE in man and mouse. 
 
In order to further test this X chromosome dose hypothesis, we asked whether having a third X 
chromosome increases the risk of developing SLE or other autoimmune diseases. Trisomy X 
(47,XXX) is present in approximately 1 out of every 1000 live-born girls(12, 13). There are no 
consistently recognized abnormalities in sex hormone levels, sexual development, fertility, or 
pregnancy(14), though premature ovarian failure has been associated with carriage of 
47,XXX(15-17). One suggested phenotype difference is that 47,XXX women may have more 
anxiety and shyness and lower self-esteem(18). In fact, 47,XXX is usually unrecognized, with 
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over 90% of the patients undiagnosed unless patients are screened for chromosomal 
abnormalities for other reasons(14). Herein, we show that 47,XXX is enriched among patients 
with SLE and SS, but not enriched in patients with PBC, RA or the non-autoimmune disease 
sarcoidosis. 
 
Materials and Methods 
Subjects and Genotyping Methods 
We used genotyping records of subjects enrolled in multiple different genetic studies (some 
published) for this work. We excluded all male subjects from our study. To be included as a case 
in this study, subjects need to have a confirmed diagnosis of a disease of interest: SLE, SS, PBC, 
RA or sarcoidosis. For controls, we used non-affected SLE family controls, non-auto-
inflammatory subjects, population controls and non-sarcoidosis controls. A summary of 
recruitment and inclusion information for each cohort used in this study is available in the 
supplementary information (Supplementary table 1a, 1b). Institutional review boards (IRB) at 
each site provided approval for this study, and individual informed consent was obtained from all 
participants. 
 
All patients with SLE met the American College of Rheumatology (ACR) classification criteria 
for systemic lupus erythematosus(19). Subjects with SS met the 2002 American-European 
Consensus Group (AECG) classification criteria for primary Sjögren's syndrome (20). PBC 
patients met the American Association for the Study of Liver Diseases Diagnostic Criteria for 
PBC(21). Participants with RA met 1987 American College of Rheumatology criteria for the 
classification of RA (22). Sarcoidosis patients had a) tissue confirmation of granuloma, or b) 
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chest radiographic evidence of bilateral symmetrical hilar adenopathy with either a history of 
erythema nodosum or at least two years observation during which time no other disease was 
found to explain radiographic abnormalities(23-26) (Supplementary table 1a). 
 
Controls include first degree family members (sisters and mothers) of SLE patients, all of whom 
were shown not to have SLE (27). Other controls are healthy individual with no auto-
inflammatory diseases from three cohorts (28-30). Population controls of European decedents 
recruited globally were also added (31). Another population control group consisted of self-
identified African Americans receiving care at Mt. Sinai Hospital in New York. The last control 
cohorts were recruited as part of the sarcoidosis studies, and were without sarcoidosis (23-26) 
(Supplementary table 1b).  
 
Genotyping records are from various platforms: ImmunoChip [196,524 single nucleotide 
polymorphisms (SNPs), Illumina], HumanHap370 Beadchip (300,000 SNPs, Illumina). Omni1 
chip (1,134,514 SNPs, Illumina), OmniExpress chip (741,000 SNPs, Illumina) or Omni5-Quad 
chip (4,301,331 SNPs, Illumina). A summary of genotyping platforms for each cohort used in 
this study is available in the supplementary information (Supplementary table 1a, 1b). 
 
47,XXX identification 
X chromosome copy number variations were found by visually inspecting B allele frequency and 
LogR ratio (LRR) plot of each subject's X chromosome for abnormalities using Genome Studio 
(Illumina), then mean logR ratio was calculated to confirm gain of copy number. In the B allele 
frequency plot, fluorescence intensity of the B allele of any SNP is plotted over the total 
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fluorescence for that SNP in a given individual. Therefore, at a SNP with BB homozygosity the 
result is 100%, with AA homozygosity the result is 0%, and with AB heterozygosity the result is 
50%.  In the LRR plot, the fluorescence intensity of total allele A and B of the given sample is 
normalized by the reference genome to differentiate between copy number gains and losses.  
 
Normal females (46,XX) were identified by the heterozygous "three band" pattern in the B allele 
frequency plot, which corresponds to the 0%, 50%, and 100% SNP frequencies (i.e. AA, AB, 
BB). The mean logR ratio, shown by a red line at 0.0 in the LRR plot, indicates there are two 
copies of the X chromosome (Figure 1).  
 
Trisomy X (47,XXX) subjects were identified by the "four band" pattern in the B allele 
frequency plot, which corresponds to 0%, 33%, 66%, and 100% SNP frequencies (i.e. AAA, 
AAB, ABB, BBB) with the accompanying mean LRR near 0.2 (Figure 1). 
 
Fluorescence in situ hybridization (FISH) 
When cells were available, samples with chromosome abnormalities identified by B allele 
frequency and LRR plots were validated by FISH, as previously reported(32). For subjects that 
had frozen peripheral blood mononuclear cells (PBMCs), we used commercial FISH probes that 
recognize the centromeres of chromosomes X and Y to confirm aneuploidies of chromosome X 
(alpha-satellite repeats DXZ1 & DYZ3, PID# KI-20030, Veridex). Fifty nuclei were scored for 
each subject. For subjects that only had Epstein-Barr virus transformed B lymphocyte cell lines 
(LCLs or lymphoblastoid cell lines) available, we used commercial FISH probes that recognize 
the X centromeres, Yp and chromosome 18 (DXZ1, DYZ3 and D18Z1, Vysis) to confirm 
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aneuploidies of chromosome X. Chromosome 18 probe signals served as controls to establish 
that the cell lines tested had a normal diploid genome. Two hundred nuclei were scored for each 
subject. Possible mosaicism was assessed according to the percentage of 45,X, 46,XX, or 
47,XXX cells enumerated (Figure 2).  
 
Polymerase Chain Reaction (PCR) 
47,XXX samples having only DNA available were confirmed by PCR using TaqMan® copy 
variation assays (Life technology). Copy number of a gene on the X chromosome (YIPF6) was 
normalized to TaqMan® copy number reference assay, RNase P, on chromosome 14. Real time 
PCR was performed on an Applied Biosystems 7500 thermocycler. Data were analyzed using 
CopyCaller v2.0 software (Figure 3).  
 
Quality control and statistical analysis 
Subjects that had a call frequency lower than 0.90, genetically XY individuals self-reported as 
females, subjects whose samples indicated mixing of samples from multiple individuals or 
duplicated samples were removed.  
 
The enrichment of 47,XXX in SLE, SS, PBC, RA subjects versus control subjects were tested by 
two-tailed Fisher’s exact test using R (Version 3.2.2) (Table 1).   
 
The prevalence of SLE and SS among women with 47,XXX was estimated using Bayes’ 
theorem.  Below are the Bayes’ theorem (P [B/A] = (P [A/B]*P [B])/P [A]) calculations to 
estimate the prevalence of SLE and Sjögren’s syndrome in females with 47,XXX.  
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A = the frequency of trisomy X, B = the frequency of SLE or SS in females, P [A/B] represents 
frequency of individuals with 47,XXX in SLE or SS, and P [B/A] would indicate the probability 
of SLE or SS within the group with trisomy X.  
Condition   Prevalences used in the Bayes’ theorem calculations 
1) SLE    = 1 in 1,000 women in the USA(2)  
2) SS    = 1 in 200 women in the USA(33)  
3) 47,XXX                = 1 in 1,000 women(34) 
4) 47,XXX with SLE    = 1 in 404 SLE women (data from this study) 
5) 47,XXX with SS               = 1 in 344 SS women (data from this study) 
The Bayes’ theorem calculations:  
Prevalence of S𝐿𝐸 𝑖𝑛 females with 47, 𝑋𝑋𝑋 
= [𝐹𝑟𝑒q (47, 𝑋𝑋𝑋 𝑖𝑛 𝑆𝐿𝐸) ∗𝐹𝑟𝑒𝑞 (𝑆𝐿𝐸 𝑖𝑛 𝑓𝑒𝑚𝑎𝑙𝑒s)] / 𝐹𝑟𝑒𝑞 (47, 𝑋𝑋𝑋 𝑖𝑛 𝑓𝑒𝑚𝑎𝑙𝑒s) 
Prevalence of SS 𝑖𝑛 females with 47, 𝑋𝑋𝑋 
= [𝐹𝑟𝑒q (47, 𝑋𝑋𝑋 𝑖𝑛 𝑆S) ∗𝐹𝑟𝑒𝑞 (𝑆S 𝑖𝑛 𝑓𝑒𝑚𝑎𝑙𝑒)] / 𝐹𝑟𝑒𝑞 (47, 𝑋𝑋𝑋 𝑖𝑛 𝑓𝑒𝑚𝑎𝑙𝑒s) 
 
Population stratification was performed using SNP & Variation Suite software (Golden Helix) 
for SLE cases and controls. European ancestry and African ancestry were segregated within 3 
s.d. of the mean of the first 2 principal components. Non-European or African ancestry subjects 
were dropped as well as the ones that their self-identified races did not match the principal 
component analysis results. Logistic regression modeling in R (Version 3.0.0) using glm 
function was performed to adjust odds ratio values for ancestry. 
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To confirm our results were not due to biases in the control groups, we also performed tests 
comparing 47,XXX enrichment in our case subjects to different control groups. The enrichment 
of 47,XXX in SLE versus non-affected SLE family controls was tested by two-tailed Fisher’s 
exact test using R (Version 3.2.2). The enrichment of 47,XXX in SS versus healthy non-auto-
inflammatory controls was also tested by two-tailed Fisher’s exact test using R (Version 3.2.2). 
The enrichment of SLE and SS subjects versus a) controls without non-sarcoidosis subjects, b) 
controls without population controls and c) controls without non-sarcoidosis and population 
controls were also tested by two-tailed Fisher’s exact test using R (Version 3.2.2). Finally, the 
same analysis was used to test the enrichment of 47,XXX in SLE, SS, PBC, RA subjects versus 
unselected newborn infants controls as reported by Jacob et.al(34). 
 
 
Results 
Subjects 
After quality control, we had 2826 SLE, 1033 SS, 1118 PBC, 1710 RA, 939 sarcoidosis and 
7074 control subjects for our study. For controls, we had 2090 non-affected first degree family 
member of SLE patients, 1684 non-auto-inflammatory healthy control subjects, 2680 population 
control subjects and 620 non-sarcoidosis control subjects (Supplementary table 1a, 1b). There 
is no difference in prevalence of 47,XXX between SLE family control versus the rest controls by 
Fisher exact test (p=1, data not shown). A risk with the population controls is that some subjects 
might have the diseases of interest because this group represents a general population and was 
not specifically screened for the diseases of interest to this study. The non-sarcoidosis controls 
(n=620) may also contain subjects with diseases of interest (other than sarcoidosis) but the 
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smaller number of subjects makes it less likely to contain SLE/SS/PBC/RA patients. Since the 
non-sarcoidosis control and population control each contains one of the two 47,XXX in the 
controls, we decided to retain them for modeling purpose. This decision potentially biases our 
results towards the null hypothesis. We therefore considered all three control cohorts in 
aggregate for our primary analysis. 
 
47,XXX enrichment in systemic lupus erythematosus and primary Sjögren’s syndrome 
Using single nucleotide polymorphism typing of the X chromosome, we found 47,XXX in seven 
of 2,826 women with SLE and in three of 1,033 women with SS, but only two in the 7,074 
controls (p=0.003, OR=8.78, 95% CI: 1.67-86.79 and p=0.02, OR=10.29, 95% CI: 1.18-123.47; 
respectively; Table 1, Fig. 1). Five of the seven 47,XXX subjects with SLE were validated by 
FISH (Fig. 2). We validated one using frozen PBMCs and another four using lymphoblastoid 
cell lines (LCLs). Four subjects had 100% of 47,XXX cells, one had 98.5% of 47,XXX cells and 
1.5% of 48,XXXX cells, which led us to consider this subject with the other 47,XXX subjects.  
We validated the two other 47,XXX subjects with SLE and the three with primary SS using q-
PCR, which demonstrated a three X chromosome complement in all five DNA samples (Fig. 3). 
No DNA or cells were available from the two 47,XXX controls, but the complete fidelity 
between the genotyping screening and more traditional method supports the likelihood of 
accuracy in these samples. 
 
Thus, we find that 1 in 404 (95% CI: 196-1004) women with SLE and 1 in 344 (95% CI: 115-
1620) with SS have 47,XXX, ~2.5 and ~2.9 times higher, respectively, than the published 
population prevalence of 47,XXX which is ~1/1000(12, 13).  
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Controls in this study consisted of non-affected SLE family members, non-auto-inflammatory 
subjects, population controls, and non-sarcoidosis controls. The best controls for the SLE 
patients are the 2090 non-affected SLE family members. However, there are no 47,XXX 
participants found in this control cohort. There is a significant difference in 47,XXX enrichment 
when comparing SLE patients only to the family control cohort(Supplementary table 3). The 
non-affected SLE family members could possibly contain subjects with SS, so we tested 
47,XXX enrichment in SS with only the 1684 healthy non-auto-inflammatory controls and the 
results remained significant (Supplementary table 4). The 2680 population controls and 620 
non-sarcoidosis controls could potentially contain subjects with SLE or SS. We tested 47,XXX 
enrichment in SLE and SS with the removal of either or both of these control datasets and the 
results remained significant(Supplementary table 5a, 5b, 5c). We also compared 47,XXX in 
SLE and SS with a published unselected new born infants 47,XXX screening datasets (n=20,790) 
(34). Since a reported 47,XXX  phenotype is increased anxiety and shyness combined with lower 
self-esteem(18), we feared 47,XXX participants potential may be less willing to participate in 
research studies, although this should equally affect case and control recruitment. Using the 
unselected new born infants’ dataset should have no recruitment bias but a potential bias in cases 
remains. We still have a significant enrichment of 47,XXX in SLE (p=0.036, OR=2.58, 95% CI: 
0.92-6.36) and the same trend for 47,XXX enrichment in SS (p=0.093, OR=3.02, 95% CI: 0.57-
10.22) (Supplementary table 6). We are therefore inclined to conclude that the comparison with 
the combination of all control cohorts is a fair representation of the enrichment in SLE and SS. 
The loss of significance in SS maybe due to small sample size. 
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Using the published population prevalence of 47,XXX in the population (~1/1000) and Bayes’ 
theorem(9, 12, 13), we predict that SLE exists in 1 of 404 women with 47,XXX and SS in 1of 69 
women with 47,XXX. This calculation assumes that SLE is present in 1/1,000, and SS in 1/200 
women in the USA. We estimate the prevalence of SLE and SS with 47,XXX is ~2.5 times 
higher than that with 46,XX and ~25 and ~41 times higher than 46,XY, respectively (Table 3).  
 
47,XXX risk is independent of ancestry 
Individuals of African ancestry have a higher risk for SLE compared to those of European 
ancestry(35), and we observed a majority of the 47,XXX subjects self-identified as of African 
ancestry. While there are no studies on 47,XXX prevalence by ancestry, there is a study 
demonstrating 47,XXY differences by ancestry(34). Therefore, we asked whether the SLE risk 
associated with 47,XXX is dependent on ancestry. After population stratification, 375 samples 
were categorized as non-European/African ancestries and therefore excluded. An additional 144 
samples were dropped because of a self-identified race mismatch with the principal component 
analysis, giving us a final of 1592 subjects of African ancestry (AA) and 1083 subjects of 
European ancestry (EA) with SLE, along with 3755 AA and 2951 EA control subjects. Among 
the seven 47,XXX women with SLE, five self-identified as being of African ancestry, and two of 
European ancestry. The two control 47,XXX women self-identified as of African ancestry. After 
principal component analysis for population stratification, one African ancestry SLE 47,XXX 
subject was removed as an admixed outlier (Table 2). We performed logistic regression analysis 
of SLE status with 47,XXX and ancestry as independent variables. The ancestry adjusted OR 
was 7.36 with p=0.01, similar to the unadjusted model (Supplementary Table 2). We also 
modeled using the interaction term between ancestry and 47,XXX to test for effect modification, 
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but the interaction term was not significant. So we conclude that the odds of 47,XXX in SLE is 
independent of African ancestry in our data.   
   In addition, there was an increased incidence of 47,XXX among the SS patients. The SS 
patient cohort was almost entirely comprised of individuals of European ancestry (>95%); all 
three 47,XXX SS cases self-identified as being of  European ancestry.  This meant we were 
unable to adjust for ancestry effects in SS.  
 
47, XXX in other autoimmune diseases 
We found 47,XXX in 1 of 1,118 women with PBC, 1 of 1,710 with RA, and none of 939 with 
sarcoidosis (p>0.05, Table 1). The 47,XXX subject with PBC was validated to have three X 
chromosomes with q-PCR (Figure 3). No DNA or cells were available for the 47,XXX subject 
with RA. There was no statistically significant increase in prevalence of 47,XXX seen in PBC, 
RA or sarcoidosis compared to our controls. The comparison of 47,XXX in PBC, RA and 
sarcoidosis to the unselected newborn infants dataset also found no significant difference 
(Supplementary table 6). 
 
Discussion 
We showed that 47,XXX is more frequent in patients with SLE and SS. Indeed, this and previous 
work show that the risk of SLE and SS increases with each additional X chromosome (Table 3). 
The ~25-fold increase in predicted prevalence for SLE and ~41-fold increase for SS observed in 
47,XXX women compared to 46,XY men reveals an effect on risk exceeding by many fold that 
of all other known genetic risk factors for SLE or SS. The importance of these findings is not for 
the few individuals with 47,XXX, but rather lies in the fact that rare events and phenotypes 
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reveal insights into the mechanism for the general disease circumstances. Everyone has an X 
chromosome, and increased 47,XXX among women with either SLE or SS informs the potential 
mechanism underpinning the disparate risk of these diseases found for men and women with a 
normal sex chromosome complement. Because sexual development and sex hormones are 
normal in 47,XXX women, these data suggest that the number of X chromosomes is a key factor 
imparting the 10-fold risk difference between men and women.   
 
Because 47,XXX is a rare event, in order to get a sufficiently large sample size, we included 
non-affected SLE family controls, non-auto-inflammatory subjects, population controls and non-
sarcoidosis controls in our study. The 2090 non-affected SLE family controls may contain 
subjects with SS, we showed that when comparing 47,XXX enrichment in SS only with the 
healthy non-auto-inflammatory controls, the result is still significant (Supplementary table 4). 
The 2680 population control and 620 non-sarcoidosis controls may contain subjects with SLE or 
SS. We showed that even when removing these control groups, our 47,XXX enrichment in SLE 
and will still be significant if not more so (Supplementary table 5a,5b,5c).  One possible 
phenotype associated with 47,XXX is anxiety, shyness and low self-esteem(18), a potential 
source of bias as 47,XXX subjects may be less willing to participate in research studies. This 
raises the question of whether 47,XXX would be less willing to participate in our study. We 
think this personality trait of 47,XXX women would lead to a non-differential error that would 
equally affect both case and control group recruitment. The majority (90%) of the 47,XXX are 
unrecognized(14), which means they only rarely exhibit a clear phenotype or that any phenotype 
is typically mild. We also compared our rate of 47,XXX in SLE, SS, RA, PBC, and sarcoidosis 
with a published unselected new born infants 47,XXX screening dataset(34). The newborn infant 
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dataset has no bias in recruitment since consecutive births were studied (Supplementary table 
6). Even in this case, we still have a significant enrichment of 47,XXX in SLE and a trend for 
47,XXX enrichment in SS, which supports our hypothesis of X chromosome does effect in SLE 
and SS.  
 
We did not find excess 47,XXX among women with the other autoimmune diseases studied here 
(PBC and RA) compared to our controls or the unselected newborn infant dataset (Table 1, 
Supplementary table 6).  While it is possible that we had inadequate sample size for PBC and 
RA, the relationship of Turner’s syndrome (45,X) to autoimmunity also suggests heterogeneity 
in the mechanisms of the sex bias found in autoimmune diseases. Autoimmune thyroiditis, type 1 
diabetes mellitus, and celiac disease are found in excess among Turner’s syndrome (45,X) 
patients(36). On the other hand, there is no evidence that prevalence of SLE or SS are increased 
in Turner’s syndrome. While rarer than the Turner’s-associated diseases, the paucity of Turner’s 
syndrome among SLE patients (37, 38) suggests that SLE risk in these patients is more similar to 
46,XY males rather than to 46,XX females. Moreover, PBC, autoimmune thyroid disease 
(AITD) and systemic sclerosis have increased acquired X-monosomy but SLE does not(7, 8, 39), 
also suggesting existence of multiple mechanisms for sex bias in autoimmunity.  
 
If SLE and 47,XXX both occur at 1 in ~1000 and were independent, then only 1 in a million 
women would have both SLE and 47,XXX.  Our data suggest that both are coincident at 1 in 
~40,000 women. The SLE families provide an interesting insight into how these risks may be 
modified. There are 7 women with SLE and 47,XXX in our sample of 2826 SLE cases, but no 
primary female relatives of SLE patients with 47,XXX among the 2090 subjects we examined. 
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That this difference is significant (p=0.02) suggests that 47,XXX is a strong contributor to SLE 
when present within the family milieu of other genetics and environmental factors that establish 
risk for SLE (Supplementary table 3). 
 
Sex hormones have long been considered a candidate mechanism of gender bias. We previously 
reported Klinefelter’s men (47,XXY) have a similar risk of SLE as women (46,XX) (9), while in 
the present study, 47,XXX women, who do not produce abnormal sex hormones(14, 40), have 
excess risk for SLE and SS compared to 46,XX women. Furthermore, there is no difference in 
the levels of sex hormones between SLE patients at disease onset and healthy controls(41). Other 
data suggest that sex hormone levels in men with SLE are abnormal, but similar to those found in 
men with other non-female-biased chronic illnesses(42).  The female bias in SLE also exists 
before puberty with girls being five times more likely to develop SLE than boys(43). Similarly, 
the sex bias in SLE is unaffected by the lower estrogen levels after menopause, and is not 
statistically different from those with disease onset in the reproductive years(44). These 
observations suggest that X chromosome dose contributing to sex bias in SLE is independent of 
hormonal effects. X chromosome dose effect predisposes women to greater susceptibility to SLE 
and SS. 
 
Perhaps the observation of a global reduction in methylation in SLE by Richardson and 
colleagues in activated T cells of SLE patients (45) offers possible explanations for a gene dose 
hypothesis. Each additional X chromosome, which is normally inactivated by methylation, could 
exert an effect if methylation is reversed or if additional X chromosomes affected methylation-
related regulation of autosomal genes. Alternatively, a gene or gene(s) that escapes X 
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inactivation (46), producing a gene-dose effect could be an explanation. Support for above 
mechanisms has not yet been developed.  
 
To conclude, the available data strongly support a genetic cause of the powerful female bias in 
SLE and SS being located on the X chromosome with a mechanism that appears to be at least 
partially independent of circulating sex hormones. Our new data demonstrating increased risk of 
SLE and SS among 47,XXX women indicate that the female bias may be explained, at least in 
part, by an X chromosome gene dose effect. Identifying the specific properties of the X 
chromosome responsible for the increase in SLE and SS risk will be critical for advancing the 
understanding of these disorders. 
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Tables 
Table 1. 47,XXX incidence. 47,XXX in systemic lupus erythematosus (SLE), primary Sjögren's 
syndrome (SS), primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), sarcoidosis and 
controls. Each disease state is compared to the control group. P-value, OR with 95% CI were 
calculated by Fisher exact test. 
Disease 
F/M 
ratio 
Sample 
Size 
47,XXX 
Odds Ratio 
(95%CI) 
p value Incidence 
Systemic lupus 
erythematosus 
10:1 2826 7 
8.78 
(1.67-86.79) 
0.003 1/404 
Sjögren’s syndrome 14:1 1033 3 
10.29 
(1.18-123.47) 
0.02 1/344 
Primary Biliary 
Cirrhosis 
10:1 1118 1 
3.16 
(0.05-60.89) 
NS 1/1118 
Rheumatoid Arthritis 2~3:1 1710 1 
2.07 
(0.03-39.75) 
NS 1/1710 
Sarcoidosis - 939 0 - - - 
Controls - 7074 2 - - 1/3537 
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Table 2. Numbers of 47,XXX by ancestry in SLE cases and controls. 
 Disease Race 47,XXX Sample Size Total 
Systemic lupus erythematosus 
AA 4 1592 
2675 
EA 2 1083 
Controls 
AA 2 3755 
6706 
EA 0 2951 
Total 
AA 6 5347 
9381 
EA 2 4034 
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Table 3. Systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS) 
relative risk with X chromosome numbers.  
X number Karyotype SLE Relative Risk SS Relative Risk 
1 45X; 46XY 1 1 
2 46XX; 47XXY* ~10 ~14 
3 47XXX ~25 ~41 
*47,XXY data with Sjögren's syndrome is not available here. 
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Figures 
 
Fig. 1. 47,XXX identification. B allele frequency and logR ratio plot of 46,XY from a 
representative normal man (first panel, for comparison purposes only as men were not included 
in the present study), 46,XX from a normal woman (second panel) and 47,XXX from a trisomy 
X syndrome patient (third panel). 
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Fig. 2. 47,XXX validation by fluorescence in situ hybridization assay (FISH). Validation of 
46,XX from a normal female (upper) and 47,XXX from a trisomy X syndrome patient (bottom). 
The images are showing a single representative nucleus. 200 nuclei were counted. 
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Fig. 3. 47,XXX validation by PCR. DNA amplification validation of 47,XXX for two systemic 
lupus erythematosus patients (SLE1, SLE2), two primary Sjögren's syndrome patients (SS1, 
SS2) and one primary biliary cirrhosis patient (PBC1).  As calibrators, we used known 47,XXX 
(shown in blue), 46,XX (shown in red) and 45X (shown in purple) samples. Calibrators were all 
validated by FISH and used to determine copy number in the experimental samples. 
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Supplementary Table 1a. Recruitment information of patient datasets. Pre- and post-quality control (QC) numbers, genotyping 
platforms, recruitment strategies, criterias, locations, time and references are listed for SLE, SS, PBC, RA and sarcoidosis patient 
datasets. Age information is unavailable. 
Datasets 
Pre 
QC 
Post 
QC 
Genotyping 
platform 
Recruitment strategy Recruitment Criteria Recruitment locations Recruitment time Reference 
SLE 3449 2826 
Omni 1, and 
immunochip 
Consent in clinics 
American College of Rheumatology (ACR) 
classification criteria for systemic lupus 
erythematosus 
Cedars-Sinai Medical Center, California; Hospital for special surgery, New York; Oklahoma Medical Research Foundation, 
Oklahoma; University of Alabama at Birmingham, Alabama; Univeristy of Chicago,Illinois; University of Michigan, 
Michigan; University of Minnesota, Minnesota; United states; 27 subjects unknown 
976 subjects: before 
2010; 1821 subject: 
1992-2010; 29 subjects 
unknown 
Not 
published 
SS 1238 1033 Immunochip Consent in clinics 
American-European Consensus Group (AECG) 
classification criteria for primary Sjögren's syndrome 
Newcastle University, United Kingdom; National Institue of Health, USA; Uppsala University Hospital, Sweden; Karolinska 
Institute, Sweden; The Queen Elizabeth Hospital and University of Adelaide, Australia; Stavanger University Hospital, 
Norway; University of Bergen, Norway; Université Paris-Sud, France 
N/A (31) 
PBC 1564 1118 
HumanHap 370 
Beadchip; 
Immunochip 
Consent in clinics 
American Association for the Study of Liver Diseases 
Diagnostic Criteria for PBC 
Canada, United States and Europe 2005-2012 (47, 48) 
RA_1 453 449 
HumanHap 370 
Beadchip 
Consent in clinics 
1987 American College 
of Rheumatology criteria for the classification of RA 
Toronto, Canada 2004-2008 (30) 
RA_2 1290 1261 Immunochip Consent in clinics 
1987 American College 
of Rheumatology criteria for the classification of RA 
Argentina, Mexico, Peru and Chile 2008-2010 (49) 
Sarcoidosis 956 939 Omni 1 
Consent in clinics, 
recruit from health fairs, 
advertise through media, 
hospital and church 
Tissue confirmation of granuloma; or had chest 
radiographic evidence of bilateral symmetrical hilar 
adenopathy and either a history of erythema nodosum 
or at least two years observation during which time 
no other disease was found to explain radiographic 
abnormalities 
Beth Israel Deaconess Medical Center, Massachusetts; Georgetown University Medical Center, Washington D.C.; Case 
Western Reserve University and University of Cincinnati Medical Center, Ohio; Henry Ford Health system, Michigan; Johns 
Hopkins University School of Medicine, Maryland; Medical University of South Carolina, South Carolina; Mount Sinai 
Medical Center, Florida; National Jewish Medical and Research Center, Colorado; University of Iowa College of Medicine, 
Iowa; University of Pennsylvania and Allegheny University of the Health Sciences, Pennsylvania; United States. 429 
subjects unknown. 
167 subject: 1996-1999; 
429 subjects: late 90’s 
to early 2000’s; 343 
subjects: unknown 
(23-26) 
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Supplementary Table 1b. Recruitment information of control datasets. Pre- and post-QC numbers, genotyping platforms, 
recruitment strategies, criterias, locations, time and references are listed for control datasets. Age information is unavailable. 
Datasets 
Pre  
QC 
Post 
QC 
Genotyping 
platform 
Recruitment strategy Recruitment criteria Recruitment locations Recruitment time Reference 
Non-affected SLE family controls 2408 2090 Immunochip Consent in clinics 
First degree lupus family members 
(mothers and sisters) who have no SLE 
United States 1990-2010 (27) 
Healthy 
individuals, with no 
auto-inflammatory 
diseases 
Cincinnati 
cohorts 
501 497 Omni5 
Community-based 
recruitment strategies: 
including visits to 
neighborhood schools and 
day-care centers 
Healthy individuals without known 
major health conditions recruited from 
the geographic area served by 
Cincinnati Children's Hospital Medical 
Center (CCHMC) 
Cincinnati, OH, United States Sept 2006-Oct 2010 (28) (29) 
RDRCC 
cohorts 
792 747 Immunochip 
Consent in community 
clinics, recruit in health 
fair and employer 
sponsored recruiting 
events 
Healthy individuals recruited who were 
screened negative for autoimmune 
rheumatic disease by a validated 
questionnaire(50) 
Oklahoma, United States 2009-2010  Not published 
Canada 
cohort 
452 440 
HumanHap 370 
Beadchip, 
Immunochip 
Advertise through flyer 
Individuals of European origin from 
the Toronto area who had no history of 
rheumatoid arthritis or other 
inflammatory disease 
Toronto, Canada 2005-2011 
(30), data for 
112 subjects 
not published 
Population Controls 
SS controls 465 352 Immunochip N/A Population controls 
Uppsala University Hospital, Sweden; Karolinska Institute, Sweden; The Queen Elizabeth Hospital and 
University of Adelaide, Australia; Oklahoma Medical Research Foundation, USA; Stavanger University 
Hospital, Norway; University of Bergen, Norway; University of Minnesota, USA 
N/A (31)  
AA 
controls 
2379 2328 OmniExpress Consent in clinics 
African American patients receiving 
care at Mount Sinai without selection 
for any specific condition requirements 
Mt Sinai Medical School hospitals 2007-2012 Not published 
Sarcoidosis controls 639 620 Omni1 
Consent in clinics, recreuit 
in health fairs, advertise 
through media, hospital 
and church 
Non-sarcoidosis 
Beth Israel Deaconess Medical Center, Massachusetts; Georgetown University Medical Center, 
Washington D.C.; Case Western Reserve University and University of Cincinnati Medical Center, Ohio; 
Henry Ford Health system, Michigan; Johns Hopkins University School of Medicine, Maryland; Medical 
University of South Carolina, South Carolina; Mount Sinai Medical Center, Florida; National Jewish 
Medical and Research Center, Colorado; University of Iowa College of Medicine, Iowa; University of 
Pennsylvania and Allegheny University of the Health Sciences, Pennsylvania; United States. 106 subjects 
unknown. 
186 subject: 1996-1999; 
105 subjects: late 90’s 
to early 2000’s; 329 
subjects: unknown 
 (23-26) 
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Supplementary Table2. Adjusted and unadjusted OR of 47,XXX in SLE. 
Logistic regression modeling OR p-value 
Model 1 (47,XXX only) 7.53 0.01 
Model 2 (47,XXX and ancestry) 7.36 0.01 
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Supplementary Table 3. 47,XXX enrichment in SLE (compared to non-affected SLE family 
members). 47,XXX in systemic lupus erythematosus (SLE) and non-affected SLE family 
controls. *Modified p-value, OR with 95% CI were calculated by fisher exact test through 
adding 0.5 into each cell to solve the issue of zero 47,XXX in the controls. 
Disease phenotype Sample Size 47, XXX p-value OR(95% CI) 
Systemic lupus erythematosus 2826 7 0.02 11.12 (1.26-inf) 
Non-affected SLE family controls 2090 0 - - 
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Supplementary Table 4. 47,XXX enrichment in SS (compared to healthy non-auto-
inflammatory controls). 47,XXX in Sjögren's syndrome (SS) and healthy non-auto-
inflammatory controls. *Modified p-value, OR with 95% CI were calculated by fisher exact test 
through adding 0.5 into each cell to solve the issue of zero 47,XXX in the controls. 
Disease phenotype Sample Size 47, XXX p-value OR(95% CI) 
Sjögren's syndrome 1033 3 0.02  11.44(1.08-inf) 
Healthy non-auto-inflammatory controls 1684 0 - - 
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Supplementary Table 5a. 47,XXX enrichment in SLE and SS (compared to controls 
without non-sarcoidosis control cohort). 47,XXX in systemic lupus erythematosus (SLE), 
primary Sjögren's syndrome (SS) and controls without non-sarcoidosis controls. Each disease 
state is compared to controls without non-sarcoidosis controls. P-value, OR with 95% CI were 
calculated by Fisher exact test. 
Disease phenotype Sample Size 47, XXX p-value OR(95% CI) 
Systemic lupus erythematosus 2826 7 0.001 16.02 (2.06-719.67) 
Sjögren's syndrome 1033 3 0.009 18.78 (1.51-980.69) 
Controls (No non-sarcoidosis) 6454 1 - - 
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Supplementary Table 5b. 47,XXX enrichment in SLE and SS (compared to controls 
without population control cohort). 47,XXX in systemic lupus erythematosus (SLE), primary 
Sjögren's syndrome (SS) and controls without population controls. Each disease state is 
compared to controls without population controls. P-value, OR with 95% CI were calculated by 
Fisher exact test. 
Disease phenotype Sample Size 47, XXX p-value OR(95% CI) 
Systemic lupus erythematosus 2826 7 0.007 10.90 (1.40-490.58) 
Sjögren's syndrome 1033 3 0.02 12.79 (1.03-669.11) 
Controls (No population controls) 4394 1 - - 
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Supplementary Table 5c. 47,XXX enrichment in SLE and SS (compared to controls 
without non-sarcoidosis and population control cohorts). 47,XXX in systemic lupus 
erythematosus (SLE), primary Sjögren's syndrome (SS) and controls without both non-
sarcoidosis controls and population controls. Each disease state is compared to controls without 
non-sarcoidosis and population controls. *Modified p-value, OR with 95% CI were calculated by 
fisher exact test through adding 0.5 into each cell to solve the issue of zero 47,XXX in the 
controls. 
Disease phenotype 
Sample 
Size 
47, XXX p-value* Modified OR(95% CI)* 
Systemic lupus erythematosus 2826 7 0.001 20.08 (2.28-inf) 
Sjögren's syndrome 1033 3 0.002 25.64 (2.41-inf) 
Controls (No non-sarcoidosis 
and population controls) 
3774 0 - - 
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Supplementary Table 6. 47,XXX incidence (compared to unselected newborn infants 
cohort). 47,XXX in systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), 
primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), sarcoidosis and unselected newborn 
infants. Each disease state is compared to the unselected newborn infants group. P-value, OR 
with 95% CI were calculated by Fisher exact test. 
Disease phenotype Sample Size 47, XXX OR(95% CI) p-value 
Systemic lupus erythematosus 2826 7 2.58 (0.92-6.36) 0.036 
Sjögren's syndrome 1033 3 3.02 (0.57-10.22) 0.093 
Primary biliary cirrhosis 1118 1 0.93 (0.02-5.82) 1 
Rheumatoid arthritis 1710 1 0.61 (0.01-3.80) 1 
Unselected newborn infants(34) 20790 20 - - 
 
 
